Corbus Pharmaceuticals Holdings, Inc.
CRBP
$6.63
$0.508.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 78.84% | 3.38% | -0.05% | -6.54% | -10.28% |
| Gross Profit | -78.84% | -3.38% | 0.05% | 6.54% | 10.28% |
| SG&A Expenses | 20.99% | 18.62% | 3.03% | -14.76% | -20.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.40% | 8.08% | 0.98% | -9.58% | -14.24% |
| Operating Income | -57.40% | -8.08% | -0.98% | 9.58% | 14.24% |
| Income Before Tax | -48.97% | 9.85% | 18.46% | 24.29% | 33.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.97% | 9.85% | 18.46% | 24.29% | 33.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.97% | 9.85% | 18.46% | 24.29% | 33.36% |
| EBIT | -57.40% | -8.08% | -0.98% | 9.58% | 14.24% |
| EBITDA | -58.61% | -8.32% | -1.16% | 9.48% | 14.17% |
| EPS Basic | 39.37% | 64.71% | 57.99% | 47.14% | 42.56% |
| Normalized Basic EPS | 39.37% | 64.71% | 58.15% | 47.34% | 36.51% |
| EPS Diluted | 39.37% | 64.71% | 57.99% | 47.14% | 42.56% |
| Normalized Diluted EPS | 39.37% | 64.71% | 58.15% | 47.34% | 36.51% |
| Average Basic Shares Outstanding | 121.36% | 151.68% | 109.93% | 67.91% | 28.40% |
| Average Diluted Shares Outstanding | 121.36% | 151.68% | 109.93% | 67.91% | 28.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |